Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,585 | 503 | 99.4% |
| Consulting Fee | $23.72 | 1 | 0.3% |
| Education | $19.38 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,862 | 203 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,073 | 92 | $0 (2024) |
| Gilead Sciences, Inc. | $1,055 | 49 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $383.68 | 28 | $0 (2023) |
| PFIZER INC. | $351.60 | 24 | $0 (2024) |
| Allergan, Inc. | $320.24 | 22 | $0 (2020) |
| IRONWOOD PHARMACEUTICALS, INC | $203.65 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $202.03 | 12 | $0 (2024) |
| Janssen Biotech, Inc. | $162.88 | 12 | $0 (2023) |
| Valeant Pharmaceuticals North America LLC | $150.74 | 8 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,175 | 73 | ABBVIE INC. ($563.79) |
| 2023 | $1,118 | 74 | ABBVIE INC. ($352.27) |
| 2022 | $1,043 | 66 | ABBVIE INC. ($393.76) |
| 2021 | $651.97 | 44 | AbbVie Inc. ($232.46) |
| 2020 | $717.43 | 46 | AbbVie Inc. ($318.59) |
| 2019 | $976.99 | 68 | AbbVie, Inc. ($309.76) |
| 2018 | $929.39 | 70 | AbbVie, Inc. ($391.17) |
| 2017 | $1,015 | 65 | AbbVie, Inc. ($299.95) |
All Payment Transactions
506 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.52 | General |
| 12/03/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: IMMUNOLOGY | ||||||
| 11/23/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $0.51 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $12.03 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $11.15 | General |
| Category: Gastroenterology | ||||||
| 11/14/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $24.04 | General |
| Category: GI | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/07/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: Gastroenterology | ||||||
| 10/31/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Gastroenterology | ||||||
| 10/02/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/19/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $9.13 | General |
| Category: Gastroenterology | ||||||
| 09/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: IMMUNOLOGY | ||||||
| 09/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.53 | General |
| 08/21/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,175 | 1,296 | $575,976 | $144,595 |
| 2022 | 15 | 1,144 | 1,268 | $544,232 | $143,461 |
| 2021 | 14 | 1,376 | 1,545 | $613,982 | $168,377 |
| 2020 | 14 | 1,334 | 1,506 | $596,117 | $157,022 |
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 138 | 140 | $103,600 | $28,298 | 27.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 277 | 290 | $165,300 | $23,187 | 14.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 178 | 272 | $35,904 | $17,409 | 48.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 85 | 86 | $46,612 | $16,033 | 34.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 66 | 67 | $37,185 | $12,243 | 32.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 78 | 78 | $53,352 | $8,280 | 15.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 83 | $16,102 | $7,756 | 48.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 42 | 42 | $23,730 | $6,010 | 25.3% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 46 | 48 | $28,320 | $5,799 | 20.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 71 | 71 | $14,015 | $5,449 | 38.9% |
| 45388 | Destruction of polyp or growth of large bowel using a flexible endoscope | Facility | 2023 | 20 | 21 | $17,598 | $4,759 | 27.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 43 | 45 | $11,340 | $4,604 | 40.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $6,578 | $2,797 | 42.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 19 | 19 | $8,360 | $1,829 | 21.9% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $7,980 | $142.67 | 1.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 153 | 157 | $116,180 | $31,621 | 27.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 247 | 259 | $141,155 | $22,474 | 15.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 115 | 115 | $62,330 | $21,783 | 34.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 212 | 316 | $41,712 | $20,774 | 49.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 81 | 81 | $55,404 | $8,883 | 16.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 37 | 37 | $20,535 | $7,032 | 34.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 80 | 80 | $15,760 | $5,985 | 38.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 40 | 40 | $22,600 | $5,416 | 24.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 44 | 44 | $11,088 | $4,813 | 43.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 51 | $9,894 | $4,622 | 46.7% |
About Dr. Robert Lamport, MD
Dr. Robert Lamport, MD is a Gastroenterology healthcare provider based in Troy, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750369138.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Lamport, MD has received a total of $7,628 in payments from pharmaceutical and medical device companies, with $1,175 received in 2024. These payments were reported across 506 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($7,585).
As a Medicare-enrolled provider, Lamport has provided services to 5,029 Medicare beneficiaries, totaling 5,615 services with total Medicare billing of $613,455. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Troy, OH
- Active Since 01/05/2006
- Last Updated 01/06/2026
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1750369138
Products in Payments
- TRULANCE (Drug) $597.32
- RINVOQ (Biological) $534.44
- Humira (Biological) $524.17
- LINZESS (Drug) $426.74
- HUMIRA (Biological) $392.96
- XELJANZ (Drug) $337.35
- XIFAXAN (Drug) $313.82
- SKYRIZI (Biological) $280.65
- Creon (Drug) $221.65
- VIBERZI (Drug) $217.14
- Linzess (Drug) $203.65
- CREON (Drug) $197.45
- DIFICID (Drug) $177.33
- Entyvio (Biological) $158.11
- Mavyret (Drug) $155.26
- STELARA (Biological) $128.15
- ENTYVIO (Biological) $120.09
- MOVIPREP (Drug) $87.70
- ZEPOSIA (Drug) $86.76
- Amitiza (Drug) $84.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Troy
Dr. Partha Nandi, Md, MD
Gastroenterology — Payments: $242,021
Dr. Barry Pronold, M.d, M.D
Gastroenterology — Payments: $17,199
Dr. John Weber, Md, MD
Gastroenterology — Payments: $14,828
Dr. Mehmet Donat, Md, MD
Gastroenterology — Payments: $8,874
Dr. Richard Wille, Md, MD
Gastroenterology — Payments: $4,855
Dr. Sante Bologna, Md, MD
Gastroenterology — Payments: $3,761